Asmaa Mohamed, PhD

Currently: Postdoctoral Fellow at UVA
MCB alumna (Huang Lab)

 

About Me

After completing my undergraduate degree in Developmental Biology at the University of California, Merced in the spring of 2019 I moved to the upper valley to start my PhD in the MCB program at Dartmouth. My interest in immunology first began when I learned about the concept of immunotherapies as a sophomore in college; however, it was not until I took an immunology class that I was absolutely in love with this field and was committed to learning more about it.  I was utterly fascinated by the organization of the immune system and all its intricacies that lead to the wide array of immune responses within our bodies. As an undergrad my research primarily focused on immune cell fate decisions but upon joining the Huang Lab in 2020, I shifted my focus to tumor immunology. My current work investigates the role of myeloid cells in maintaining and generating skin tissue resident CD8 T cells in a melanoma associated vitiligo mouse model. I am passionate about science communication, teaching, writing and outreach. Outside of lab I enjoy spending time with family and friends, baking, crafting and enjoying nature.

 

Publications

Ferry SL, Abdullah L, Balasubramanian A, Nowak E, Carl A, Turnquist A, Mohamed AO, Usherwood EJ, Sundrud M, Huang YH. Systemic pre-conditioning favors effector over exhausted CD8 T cell subsets following Sup2-IL33 armored CAR T cell therapy. J Immunother Cancer 2026 Jun 3;14(6):e013020. doi: 10.1136/jitc-2025-013020.

Mohamed AO, Boone, DT, Ferry SL, Peck MC, Santos AM, Soderholm HE, Wittling MC, Paulos C, Turk MJ, Huang YH. CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors. J Immunother Cancer 2025 Feb 11;13(2):e009994. doi: 10.1136/jitc-2024-009994. PMID: 39933839.

Park C, Mohamed AO, Jarnagin HC, Bhandari R, Gunn J, Murad-Mabaera J, Kosarek NN, Kolling FW, Wilkins OM, Huang YH, Whitfield ML, Pioli PA. Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue. bioRxiv. 2025 Oct 16; pii: 2025.10.16.682860. doi: 10.1101/2025.10.16.682860. Epub 2025 Oct 16. PMID: 41279642

Hartman CJ, Mohamed AO, Shukla GS, Pero SC, Sun Y, Rodríguez RS, Genovese N, Kohler SM, Hemphill TR, Huang YH, Krag DN, Ackerman ME. Cancer therapy via neoepitope-specific monoclonal antibody cocktails. Cancer Immunol Immunother. 2025 May 31;74(7):231. doi: 10.1007/s00262-025-04075-3. PMID: 40448719

Ramirez DE, Dragnev CPC, Searles TG, Spicer N, Chen T, Lines JL, Hawkes AR, Davis WL, Mohamed A, Shirai K, Phillips JD, Rosato PC, Huang YH, Turk MJ. Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy. J Immunother Cancer. 2024 Nov 9;12(11):e010170. doi: 10.1136/jitc-2024-010170. PMID 39521617

Ramirez DE, Mohamed A, Huang YH, Turk MJ. In the Right Place at the Right Time: Trm Cells in Immunity to Cancer. Curr Opin Immunol. 2023

Mohamed A, Huang YH. Life support for transitory exhausted CTLs. Trends Immunol. 2021;42(12):1057-9. Epub 20211109. doi: 10.1016/j.it.2021.10.012. PMID: 34772619; PMCID: PMC9107299. Invited Commentary

Donham C, Chicana B, Robling AG, Mohamed A, Elizaldi S, Chi M, Freeman B, Millan A, Murugesh DK, Hum NR, Sebastian A, Loots GG, Manilay JO. Sclerostin Depletion Induces Inflammation in the Bone Marrow of Mice. Int J Mol Sci. 2021 22(17):9111. doi: 10.3390/ijms22179111. PMID: 34502021